• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    KKR Launches Allyntra, an Engineered Solutions Platform for Medical Technology and Precision Industries

    7/9/26 6:59:00 AM ET
    $KKR
    $PRM
    Investment Managers
    Finance
    Major Chemicals
    Industrials
    Get the next $KKR alert in real time by email

    Robbie Atkinson appointed as CEO and Brian Highley appointed as Chairman

    KKR today announced the launch of Allyntra ("Allyntra" or the "Company"), a newly formed precision-engineered solutions platform serving medical technology and other precision end markets. Allyntra builds on KKR’s existing investment in Precipart through its Health Care Strategic Growth Fund II, with Precipart serving as one of the foundational businesses within the platform. KKR is committing meaningful additional capital to support Allyntra’s growth by acquiring and integrating complementary best-in-class businesses and through continued investment in innovation and commercial expansion.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707491568/en/

    Robbie Atkinson will be appointed as Chief Executive Officer of Allyntra and Brian Highley as Chairman. Together, they bring deep experience building and scaling global manufacturing organizations through operational excellence and strategic leadership. Most recently, Mr. Atkinson served as CEO and President of Medical Manufacturing Technologies (MMT), where he led the company’s strategy, operations, and growth through a period of significant expansion, culminating in its successful sale to Perimeter Solutions, Inc. (NYSE:PRM). Mr. Highley brings more than 30 years of experience across the medical technology industry, having previously served as CEO of Cirtec, where he scaled the company meaningfully from two sites into one of the leading providers of end-to-end services to medical technology OEMs, including design, engineering, prototyping, and manufacturing solutions.

    "The pace of innovation across medical technology and other highly engineered industries continues to accelerate," said Robbie Atkinson, Chief Executive Officer of Allyntra. "As these technologies become more sophisticated, customers are looking for partners who can help them move faster, solve increasingly complex challenges, and bring new ideas to life. That’s exactly the opportunity I see for Allyntra."

    "Throughout my career, I’ve learned that the companies that endure are the ones that combine technical excellence with a willingness to continue evolving alongside their customers," said Brian Highley, Chairman of Allyntra. "Those are the qualities I believe will define Allyntra, and I’m excited to help shape its future by working alongside Robbie and the team."

    "Our deepened commitment to Allyntra reflects our confidence in the market opportunity and Robbie’s and Brian’s ability to bring the Allyntra vision to life. Since first investing in Precipart in 2023, we’ve become increasingly convinced of the opportunity to create a distinctive precision-engineered solutions platform. We’re pleased to continue our strategic partnership with the Laubscher family, who will remain a meaningful shareholder," said Ali Satvat, Global Head of Health Care Strategic Growth and Co-Head of Americas Private Equity Health Care at KKR, and Anuv Ratan, Managing Director at KKR.

    As part of this platform launch, Oliver Laubscher will elevate to join the Allyntra Board of Directors and transition from his role as CEO of Precipart.

    "For more than 70 years, Precipart has earned its customers’ trust through engineering excellence, innovation, and a relentless focus on quality," said Oliver Laubscher. "I look forward to continuing to work with KKR, Robbie, and Brian to support Allyntra’s next chapter of growth — building on our legacy and the culture that built it and furthering our mission to help customers "engineer possible"."

    About KKR

    KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit, and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life, and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE:KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

    About Allyntra

    Allyntra is a leading engineered solutions partner to the medical technology industry, specializing in the design, development, and manufacture of highly engineered components and assemblies for advanced surgical applications. We collaborate with the world’s leading medtech innovators to accelerate the development and commercialization of next-generation technologies, including robotic-assisted surgery, minimally invasive surgery, and advanced surgical systems.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260707491568/en/

    KKR

    Media

    media@kkr.com



    Allyntra

    Media

    media@allyntra.com

    Get the next $KKR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KKR
    $PRM

    CompanyDatePrice TargetRatingAnalyst
    Perimeter Solutions SA
    $PRM
    7/9/2026$50.00Overweight
    Analyst
    Perimeter Solutions SA
    $PRM
    6/9/2026$48.00Market Outperform
    CJS Securities
    Perimeter Solutions SA
    $PRM
    3/31/2026$30.00Neutral → Buy
    UBS
    KKR & Co. Inc.
    $KKR
    2/24/2026$137.00Outperform
    RBC Capital Mkts
    KKR & Co. Inc.
    $KKR
    1/28/2026$144.00Hold → Buy
    HSBC Securities
    KKR & Co. Inc.
    $KKR
    1/14/2026$131.00Buy → Hold
    TD Cowen
    Perimeter Solutions SA
    $PRM
    1/12/2026$31.00Buy → Neutral
    UBS
    KKR & Co. Inc.
    $KKR
    12/11/2025$176.00Buy
    UBS
    More analyst ratings

    $KKR
    $PRM
    SEC Filings

    View All

    SEC Form 144 filed by Perimeter Solutions SA

    144 - Perimeter Solutions, Inc. (0001880319) (Subject)

    6/12/26 5:21:50 PM ET
    $PRM
    Major Chemicals
    Industrials

    SEC Form 144 filed by Perimeter Solutions SA

    144 - Perimeter Solutions, Inc. (0001880319) (Subject)

    6/12/26 5:21:33 PM ET
    $PRM
    Major Chemicals
    Industrials

    KKR & Co. Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

    8-K - KKR & Co. Inc. (0001404912) (Filer)

    5/29/26 4:16:25 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    $PRM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barakett Timothy R bought $4,723,500 worth of shares (50,000 units at $94.47) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/5/26 7:30:13 PM ET
    $KKR
    Investment Managers
    Finance

    Director Dillon Mary N bought $2,021,586 worth of shares (22,225 units at $90.96) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:01 PM ET
    $KKR
    Investment Managers
    Finance

    Co-Chief Executive Officer Bae Joseph Y bought $4,428,000 worth of shares (50,000 units at $88.56) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:04 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    $PRM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Thomson Reuters and KKR Announce Joint Venture for Thomson Reuters Global Print Business

    TORONTO and NEW YORK, July 14, 2026 /CNW/ -- Thomson Reuters Corporation (TSX/Nasdaq: TRI) today announced that it has signed a definitive agreement to enter into a joint venture with KKR, a leading global investment firm. As part of the transaction, Thomson Reuters will sell a 51% stake in its Global Print business to capital accounts advised by KKR. Thomson Reuters will receive approximately $500 million in gross proceeds at closing and will retain a 49% equity interest in the joint venture. Thomson Reuters will also maintain intellectual property rights and full editorial control over its content portfolio. This new joint venture will hold an exclusive license to distribute the content in

    7/14/26 7:00:00 AM ET
    $TRI
    $KKR
    Publishing
    Consumer Discretionary
    Investment Managers
    Finance

    Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

    Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside Spero updates its cash runway guidance into the second half of 2029 CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healt

    7/14/26 6:02:00 AM ET
    $SPRO
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    KKR Leads A$400 Million Financing Solution for Ampol

    KKR, a leading global investment firm, today announced its cornerstone investment in a A$400 million (US$275 million) financing solution (the "Financing") for Ampol Limited (ASX: ALD) ("Ampol"), anchored by KKR's private credit and insurance platforms. The investment will support Ampol’s refinancing initiatives and other general corporate purposes, in line with its Capital Allocation Framework. Listed on the ASX, Ampol operates an integrated fuel supply and marketing value chain in Australia that encompasses the Lytton refinery in Queensland, an extensive national network of terminals and pipelines, and a convenience retail footprint of approximately 1,700 sites. Ampol also maintains a si

    7/12/26 6:34:00 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    $PRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Perimeter Solutions with a new price target

    Analyst initiated coverage of Perimeter Solutions with a rating of Overweight and set a new price target of $50.00

    7/9/26 9:30:24 AM ET
    $PRM
    Major Chemicals
    Industrials

    CJS Securities initiated coverage on Perimeter Solutions with a new price target

    CJS Securities initiated coverage of Perimeter Solutions with a rating of Market Outperform and set a new price target of $48.00

    6/9/26 9:29:28 AM ET
    $PRM
    Major Chemicals
    Industrials

    Perimeter Solutions upgraded by UBS with a new price target

    UBS upgraded Perimeter Solutions from Neutral to Buy and set a new price target of $30.00

    3/31/26 8:06:53 AM ET
    $PRM
    Major Chemicals
    Industrials

    $KKR
    $PRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Large owner Windacre Partnership Llc sold $195,609,062 worth of Ordinary shares (5,705,979 units at $34.28) (SEC Form 4)

    4/A - Perimeter Solutions, Inc. (0001880319) (Issuer)

    7/13/26 5:30:32 PM ET
    $PRM
    Major Chemicals
    Industrials

    Large owner Kkr Alternative Assets Llc acquired $2,422,339 worth of Class I Common Stock (105,871 units at $22.88) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    7/2/26 4:05:37 PM ET
    $KKR
    Investment Managers
    Finance

    Large owner Windacre Partnership Llc sold $195,609,062 worth of Ordinary shares (5,705,979 units at $34.28) (SEC Form 4)

    4 - Perimeter Solutions, Inc. (0001880319) (Issuer)

    6/30/26 7:51:15 PM ET
    $PRM
    Major Chemicals
    Industrials

    $KKR
    $PRM
    Financials

    Live finance-specific insights

    View All

    FSK Announces Earnings Release and Conference Call Schedule for Second Quarter 2026

    PHILADELPHIA and NEW YORK, July 9, 2026 /PRNewswire/ -- FS KKR Capital Corp. (NYSE:FSK) announced today plans to release its second quarter 2026 results before the opening of trading on the New York Stock Exchange on Thursday, August 6, 2026. FSK will host its second quarter 2026 results conference call via live webcast on Thursday, August 6, 2026 at 9:00 a.m. (Eastern Time). All interested parties are welcome to participate and can access the live webcast from the For Investors section of FSK's website at www.fskkrcapitalcorp.com under Events & Presentations or through the foll

    7/9/26 4:20:00 PM ET
    $FSK
    $KKR
    Investment Managers
    Finance

    KKR & Co. Inc. to Announce Second Quarter 2026 Results

    KKR & Co. Inc. (NYSE:KKR) announced today that it plans to release its financial results for the second quarter 2026 on Thursday, July 30, 2026, before the opening of trading on the New York Stock Exchange.A conference call to discuss KKR’s financial results will be held on Thursday, July 30, 2026 at 9:00 a.m. ET. The conference call may be accessed by dialing (877) 407-0312 (U.S. callers) or +1 (201) 389-0899 (non-U.S. callers); a pass code is not required. Additionally, the conference call will be broadcast live over the Internet and may be accessed through the Investor Center section of KKR’s website at https://ir.kkr.com/events-presentations/. A replay of the live broadcast will be avail

    7/1/26 4:15:00 PM ET
    $KKR
    Investment Managers
    Finance

    BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches

    - Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% premium to Company’s 30-day VWAP) - The financing significantly strengthens the Company’s balance sheet, enabling it to efficiently allocate capital across its highest return opportunities - The financing comes at a pivotal moment for the Company, as Attruby® continues to grow into a multi-billion-dollar blockbuster drug, and as BridgeBio prepares for three additional potential blockbuster U.S. product launches over the next 12 months across BBP-418 for LGMD2I/R9, encaleret for ADH1, and infigr

    7/1/26 7:30:00 AM ET
    $BBIO
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    $KKR
    $PRM
    Leadership Updates

    Live Leadership Updates

    View All

    KKR Launches Allyntra, an Engineered Solutions Platform for Medical Technology and Precision Industries

    Robbie Atkinson appointed as CEO and Brian Highley appointed as Chairman KKR today announced the launch of Allyntra ("Allyntra" or the "Company"), a newly formed precision-engineered solutions platform serving medical technology and other precision end markets. Allyntra builds on KKR’s existing investment in Precipart through its Health Care Strategic Growth Fund II, with Precipart serving as one of the foundational businesses within the platform. KKR is committing meaningful additional capital to support Allyntra’s growth by acquiring and integrating complementary best-in-class businesses and through continued investment in innovation and commercial expansion. This press release feature

    7/9/26 6:59:00 AM ET
    $KKR
    $PRM
    Investment Managers
    Finance
    Major Chemicals
    Industrials

    Medical Manufacturing Technologies (MMT) Appoints Grant Bowman as President to Lead the Company's Next Chapter of Growth and Innovation

    Medical Manufacturing Technologies (MMT), a Perimeter Solutions company and a leading provider of precision manufacturing technologies for the medical device and advanced industrial markets, today announced the appointment of Grant Bowman as President. Bowman will guide the company's next phase of growth while continuing MMT's customer-first approach and long-standing tradition of solving complex manufacturing challenges. As MMT enters this new phase of leadership, customers can expect the same experienced teams and responsive support across the company's Catheter, Guidewire, Abrasive, and Automation Technologies, and the company’s broader portfolio of solutions. This press release feature

    6/25/26 8:00:00 AM ET
    $PRM
    Major Chemicals
    Industrials

    KKR-led Consortium Drives Further Investment in Sylvan

    Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the "Company"), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following the investment, KKR remains the majority investor in Sylvan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120305013/en/ Founded in 1932, Sylvan is a world-leading mushroom spawn and fungal biotechnology company. The company seeks to harness the potential

    1/20/26 8:02:00 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    $PRM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Perimeter Solutions SA

    SC 13G/A - Perimeter Solutions, Inc. (0001880319) (Subject)

    11/22/24 6:42:15 PM ET
    $PRM
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/12/24 3:50:17 PM ET
    $KKR
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/4/24 11:48:27 AM ET
    $KKR
    Investment Managers
    Finance